In addition, CCT020312 administration abolished valdecoxib’s protective effect, activated the expression of p-PERK, ATF4 and CHOP and aggravated ER stress-mediated apoptosis in the OGD/R model, indicating that the inhibition of the PERK-ATF4-CHOP pathway was required for valdecoxib’s protective effect on glaucoma. The gene discussed is EIF2AK3; the disease is glaucoma.